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Abstract 
Background: In 2010, the EUPHAS 2 collaborative group created a registry with the purpose of recording data from 
critically ill patients suffering from severe sepsis and septic shock treated with polymyxin-B hemoperfusion (PMX-HP) 
for endotoxin removal. The aim of the registry was to verify the application of PMX-HP in the daily clinical practice.
Methods: The EUPHAS 2 registry involved 57 centers between January 2010 and December 2014, collecting retro-
spective data of 357 patients (297 in Europe and 60 in Asia) suffering from severe sepsis and septic shock caused by 
proved or suspected infection related to Gram negative bacteria. All patients received atleast one cycle of extracor-
poreal endotoxin removal by PMX-HP.
Results: Septic shock was diagnosed in 305 (85.4 %) patients. The most common source of infection was abdominal 
(44.0 %) followed by pulmonary (17.6 %). Gram negative bacteria represented 60.6 % of the pathogens responsible 
of infection. After 72 h from the first cycle of PMX-HP, some of the SOFA score components significantly improved 
with respect to baseline: cardiovascular (2.16 ± 1.77 from 3.32 ± 1.29, p < 0.0001), respiratory (1.95 ± 0.95 from 
2.40 ± 1.06, p < 0.001) and renal (1.84 ± 1.77 from 2.23 ± 1.62, p = 0.013). Overall 28-day survival rate was 54.5 % 
(60.4 % in abdominal and 47.5 % in pulmonary infection). Patients with abdominal infection treated with PMX-HP 
within 24 h from the diagnosis of septic shock had a 28-day survival rate of 64.5 %. Patients showing a significantly 
cardiovascular improvement after PMX-HP had a 28-survival rate of 75 % in comparison to the 39 % of patients who 
did not (p < 0.001). Cox regression analysis found the variation of cardiovascular, respiratory and coagulation SOFA to 
be independent covariates for 28-day survival. In European patients were observed a higher 28-day (58.8 vs. 34.5 %, 
p = 0.003), ICU (59 vs. 36.7 %, p = 0.006) and hospital survival rate (53.2 vs. 35 %, p = 0.02) than in Asian patients. How-
ever, the two populations were highly heterogeneous in terms of source of infection and severity scores at admission.
Conclusion: The EUPHAS 2 is the largest registry conducted outside Japan on the clinical use of PMX-HP in septic 
patients. Data analysis confirmed the feasibility of PMX-HP to treat septic patients in daily clinical practice, showing 
clinical benefits associated with endotoxin removal without significant adverse events related to the extracorporeal 
technique.
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Background
Polymyxin-B hemoperfusion (PMX-HP) [1] is a blood 
purification technique designed to bind and neutral-
ize circulating endotoxins by extracorporeal removal, 
inhibiting the progression of the septic cascade medi-
ated by lipopolysaccharide (LPS) [2–16], the core lipid 
portion of the Gram negative bacterial wall. Endotoxin is 
removed from the blood by extracorporeal hemoperfu-
sion with a polymyxin-B-adsorbing cartridge that binds 
endotoxin through covalent and ionic bonds. This ther-
apy was first introduced in Japan in 1994 and 10  years 
later it was introduced in Europe.
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The most common indication for PMX-HP has been 
septic shock due to abdominal infections. In case of 
impairment of the intestinal mucosa, LPS can translocate 
into the bloodstream. The consequent huge activation of 
the immune system can lead to the dysfunction of mul-
tiple organs until the loss of their function (MOF). The 
importance of endotoxin to determine the unfavorable 
evolution of sepsis related to Gram negative bacteria has 
been clearly demonstrated [2–15].
Several trials have been carried out to verify the 
hypothesis that removing circulating endotoxin from the 
blood of patients suffering from abdominal septic shock 
could improve their clinical outcome, in terms of organ 
dysfunction and mortality [4–15].
The Italian nationwide Early Use of Polymyxin B 
Hemoperfusion in Abdominal Septic Shock (EUPHAS) 
Randomized Control Trial (RCT) [15], demonstrated a 
significant improvement in cardiovascular response and 
outcome of patients treated by PMX-HP for severe sep-
sis and septic shock due to abdominal infections. On the 
other hand, the French ABDOMIX RCT [16] failed to 
demonstrate clinical benefits of PMX-HP application in a 
cohort of patients suffering from peritonitis-induced sep-
tic shock after emergency surgery.
Furthermore, PMX-HP has been applied in septic 
patients with source of infection different from the abdo-
men as respiratory system [17].
Due to the conflicting evidence given by EUPHAS 
and ABDOMIX RCTs in sepsis sustained by abdominal 
source of infection and new potential indication high-
lighted by case report on respiratory infections, the 
real application of PMX-HP in daily clinical practice is 
unclear.
In 2010, the EUPHAS 2 project [18] was launched, 
to create an international registry with the purpose of 
recording data from patients affected by Gram negative 
related severe sepsis and septic shock treated with PMX-
HP. The aim of the project was to evaluate the application 
of PMX-HP in the daily clinical practice, both in order 
to verify the reproducibility of data currently available 
in the literature and to evaluate the population actually 
elected for the therapy.
The EUPHAS 2 project is divided into two phases. The 
first retrospective phase aimed to collect data from at least 
250 patients. The analysis of the data from this phase was 
used to optimize the data collection for the second pro-
spective phase, which aims to collect data from a much 
larger patient population. The results from the second 
phase will be used to identify subpopulations of patients 
who may benefit from this treatment more than others.
A preliminary analysis of EUPHAS 2 retrospec-
tive phase [19] confirmed the results of EUPHAS RCT 
in abdominal septic patients. In the current paper are 
presented the full results from the first retrospective 
phase of EUPHAS 2.
Methods
The EUPHAS 2 project was a voluntary registry specifi-
cally conceived for the evaluation and analysis of PMX-
HP application in the real clinical life.
All the patients admitted to the 57 participating cent-
ers with suspected Gram negative related severe sepsis 
and septic shock unresponsive to standard care [20] were 
included in the registry. Forty-six centers were located in 
Europe (Italy, Spain and Switzerland), and eleven centers 
in Asia (India). Data collection started in January 2010 
and ended in December 2014.
The definition of severe sepsis and septic shock fol-
lowed the consensus guideline enounced by Surviving 
Sepsis Campaign [20].
The Gram negative etiology of sepsis was suspected in 
relation to the source of infection (the abdomen is colo-
nized by Gram negative species) or proven by micro-
biological tests. In 24 out of 57 centers involved in the 
registry, LPS might be assessed on peripheral blood 
sample by the neutrophil-dependent chemilumines-
cence-based endotoxin activity assay (EAA) [24]. EAA 
quantifies endotoxin levels through a relative scale rank-
ing from 0 to 1. EAA is characterized by a sensitivity of 
85.3 %, a specificity of 44 %, a negative predictive value 
of 98.6  % for the exclusion of Gram negative infection 
and 94.8 % for the exclusion of all infection [21]. Marshall 
et al. [21] demonstrated a progressive mortality increase 
related to endotoxin activity (EA) rising value. High-
est mortality rate was observed for EA greater than 0.6, 
whereby it is considered the threshold to start the LPS 
removal.
PMX-HP is not ruled by specific guidelines and this 
therapy is recommended in severe sepsis and septic shock 
unresponsive to standard care [20], caused by proved or 
suspected infection related to Gram negative bacteria. All 
patients received fluid infusion and vasopressor therapy 
if needed [20] and independently to PMX-HP.
In all patients, PMX-HP was performed using Toray-
myxin® cartridge (Toray Medical Company, Tokyo, 
Japan) connected to the patient through a 10–12 French 
veno-venous catheter inserted into the right or left femo-
ral or internal jugular vein and the pump flow rate was 
80–120 mL/min.
Each session of PMX-HP lasted 2 h. In relation to clini-
cal condition of the patient and EA (where available), the 
clinician decided to perform a second cycle of PMX-HP 
with a delay of 24 h from the first treatment.
Heparin intravenous administration as anticoagulant 
was set starting from a bolus of 3000 UI before the begin-
ning of PMX-HP with a continuous infusion of 20  UI/
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kg/h during the treatment. The recommended dose of 
heparin could be modified in relation to the hemorrhagic 
risk of the patient.
Main data collection included: timing of diagnosis of 
severe sepsis/septic shock and treatment with PMX-HP; 
hemodynamic status; septic organ function impairment; 
outcome at 28  days, ICU and hospital discharge. Septic 
progressive organ function impairment was monitored 
with SOFA score [22–25], hemodynamic status was eval-
uated with mean arterial pressure (MAP), lactates con-
centration in the blood and vasopressor load expressed as 
the inotropic core [(dopamine dose x 1) +  (dobutamine 
dose  x  1)  +  (adrenaline dose  x  100)  +  (noradrenaline 
dose  x  100)  +  (phenylephrine dose  x  100), wherein all 
doses are expressed as μg/kg/min]. SOFA score, ino-
tropic score and lactates concentration in the blood were 
assessed at the time of the first PMX-HP (t0) and every 
24 h until 72 h (t72) from t0.
Patients showing with a reduction of at least one point 
in cardiovascular SOFA between t0 and t72 were consid-
ered “cardiovascular responders”; otherwise, they were 
“cardiovascular non-responders”.
Adverse events associated with PMX-HP were recorded 
and defined as tachycardia-heart rate (HR) >100 bpm or 
HR increase >10 % HR pre-treatment during 10′ from the 
beginning of PMX-HP, hypotension-MAP <70  mmHg 
or PAM reduction >10 % MAP pre-treatment during 10′ 
from the beginning of PMX-HP, bleeding-every type of 
hemorrhagic complication, cartridge clotting-coagula-
tion of polymyxin-B fiber cartridge. Clotting of the PMX 
cartridge is an adverse event because it causes a prema-
ture interruption of the treatment (limiting its benefit) 
and blood lost for the patient.
IRBs and Ethical Committee of all centers approved 
data collection and the study.
Statistical analysis
Normality tests were performed using the Kolmogo-
rov–Smirnov test. Quantitative normally distributed 
variables (APACHE II, SAPS II, SOFA score and body 
temperature) were presented as mean ± standard devia-
tion (SD) and non-normally distributed variables (age, 
time to treatment, vasopressors, EAA and biochemical 
data) as medians and the 25th–75th quartiles range. Uni-
variate comparison was performed to compare variables 
between two groups. The organ dysfunction scores were 
compared using the unpaired t test. Categorical vari-
ables were expressed as actual numbers and percentages. 
In all comparisons, p < 0.05 was considered statistically 
significant.
Analysis was performed using R statistical software. 
Student’s t test, Wilcoxon test and Mann–Whitney test 
were used to compare means in case of normal paired or 
unpaired samples, non-normal paired samples and non-
normal unpaired samples, respectively. Fisher’s exact test 
was carried out to evaluate significance in contingency 
tables. Multiple logistic regression was performed to 
evaluate the dependence of categorical variables on one 
or more predictors, and linear multiple regression was 
used to model the dependence of scalar variables on one 
Table 1 Demographic characteristics of  patients treated 
with PMX-HP
Data are expressed as N (%) apart from otherwise indicated
a Other includes soft tissue infections, CVC-related infections, meningitides
Demographic characteristics N 357
Age, years, mean ± SD 63 (51–72)
Gender, male 240 (67.2)
SAPS II at admission, mean ± SD 50.3 ± 19.2
APACHE II at admission, mean ± SD 21.8 ± 7.2
SOFA at admission, mean ± SD 10.9 ± 3.5
Incidence of shock 305 (85.4)
Source of sepsis
 Abdominal 157 (44)
 Pulmonary 63 (17.6)
 Urinary 16 (4.5)
 Cardiac 23 (6.4)
 Trauma 19 (5.3)
 Othera 79 (22)
Patients without microbiological cultures N (%) 139 (38.9)
Patients with microbiological cultures 218 (61.1)
 Negative microbiological cultures 41 (18.8)
 Positive microbiological cultures 177 (81.1)
 Gram positive only 17 (7.8)
 Gram negative only 81 (37.2)
 Fungi only 13 (6.0)
 Mixed including gram negatives 51 (23.4)
 Mixed not including gram negatives 8 (3.7)
Patients with endotoxin activity assay, N (%) 132 (37)
 Abdominal 47 (35.6)
 Non-abdominal 85 (64.4)
 Without microbiology data 33 (25)
 Negative cultures 12 (9)
 Gram positive only 7 (5.3)
 Gram negative only 43 (32.6)
 Fungi only 14 (10.6)
 Mixed including gram negatives 21 (15.9)
 Mixed not including gram negatives 3 (2.2)
Patients with 2 treatments, N (%) 219 (61)
Patients with 1 treatment, N (%) 138 (39)
28 days survival 180 (54.5)
ICU survival 192 (55.2)
Hospital survival 172 (50)
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or more explanatory variables. Cox proportional haz-
ard model was used to relate time-to-death to multiple 
covariates. For all of the statistics tests and models, a 0.05 
significance level was considered.
Results
Demographic and clinical data of the 357 patients 
treated with PMX-HP are reported in Table  1. Data 
were recorded by 35 out of 57 centers with a median of 
patients per center of 9 [3–13] in Europe and 4.5 (2.7–11) 
in Asia.
Septic shock was diagnosed in 305 patients and severe 
sepsis in 52 patients. Eight patients had not data about 
vasopressor infused and they were considered presum-
ably affected by severe sepsis. Main sources of infection 
were the abdomen (44 %) and the lung (17.6 %).
EA was recorded in 18 out of 24 centers in which the 
assay was available. EAA was measured in 132 out of 
357 patients (37.0 %) with a median value of 0.77 (0.69–
0.90) at t0. EAA was ≥0.6 in 120 patients and <0.6 in 12 
patients, but the small number did not allowed any com-
parison between two groups.
Microbiological evidence of infection was documented 
in 174 (49.5  %) patients. Gram negative bacteria were 
isolated in 60.6 % of the microbiological samples (37.2 % 
mono-microbial and 23.4  % poly-microbial). In 139 
patients, microbiological results were either not or partly 
reported.
Each session of PMX-HP theoretically lasted 2  h. No 
data about reason (except cartridge clotting) and tim-
ing of its premature interruption were recorded in the 
registry.
The majority of patients (73.8  %) were treated within 
24  h from the onset of severe sepsis and septic shock; 
13.2 % of patients received the PMX-HP between 24 and 
48 h after the diagnosis of severe sepsis and septic shock, 
while 12.9 % of patients had a delay of more than 2 days.
Safety of Polymyxin‑B hemoperfusion
Two cycles of PMX-HP were performed in 219 patients; 
138 patients received only one treatment.
Twenty-six adverse events were recorded (two tachy-
cardias, ten hypotensions, one bleeding, thirteen car-
tridge clottings) (Additional file 1: Table S12).
Among the PMX-HP clotted cartridge, in eight patients 
was not administered heparin bolus at the beginning 
of the treatment and a lower amount of continuous 
heparin infusion was prescribed as compared to the 
recommended standard dose. No information about hep-
arin dosage was reported for the remaining five clotted 
cartridges.
None of these adverse events caused clinical worsening 
or death of the patients.
Effect of PMX‑HP on organ dysfunction
SAPS II score was 48.0 ± 16.6 in patients suffering from 
severe sepsis versus 50.5 ± 19.5 in patients suffering from 
septic shock patients. SOFA score at t0 was 8.1 ± 2.9 in 
patients suffering from severe sepsis versus 12.9 ± 4.1 in 
patients suffering from septic shock patients; 72 h from 
the beginning of PMX-HP, SOFA score decreased in 
patients suffering from septic shock, but not in patients 
suffering from severe sepsis (10.7  ±  5.4 vs 8.9  ±  4.3, 
respectively).
Table 2 shows the variations of each SOFA component 
between t0 and t72.
A significant improvement of cardiovascular 
(t0 = 3.32 ± 1.29 vs. t72 = 2.16 ± 1.77; p < 0.001), respira-
tory (t0 = 2.40 ± 1.06 vs. t72 = 1.95 ± 0.95; p < 0.001) and 
renal (t0 = 2.23 ± 1.62 vs. t72 = 1.84 ± 1.77; p = 0.013) 
scores with a reduction of inotropic score [t0  =  30.0 
(11.9–72.5) vs. t72 = 6.0 (0.0–22.0); p < 0.001] and lactate 
levels [t0 = 3.4 (1.9–6.0) vs. t72 = 1.9 (1.3–2.9); p < 0.001] 
were observed after a follow-up of 72 h. Only the coagu-
lation score significantly increased (t0 =  1.33 ±  1.29 vs. 
t72 = 1.67 ± 1.38; p = 0.004) together with platelet reduc-
tion [t0 = 117 (56–220) vs. t72 = 86 (40–163); p < 0.001]; 
both were not responsible of meaningful clinical wors-
ening. These results were confirmed excluding patients 
dead at 72 h except for renal SOFA improvement (Addi-
tional file 1: Table S1).
Length of stay and mortality
Median ICU and hospital length of stay (LoS) were 
16 days (8–29) and 28 days (16–49), respectively. Overall 
28-day survival after PMX-HP was 54.5 %. Patients with 
abdominal sepsis treated within 24 h from the diagnosis 
of septic shock had a survival rate of 64.5 %.
A Cox regression model, stratified by age, was car-
ried out to identify the independent covariates affecting 
Table 2 Variables changes 72 h after PMX-HP
Normally distributed data are expressed as mean ± SD and non-normally 
distributed data as median (interquartile range)
Italics indicates significant p values
Patients t0 N = 357 t72 N = 299 p (Wilcoxon)
SOFA score 12.4 ± 4.2 10.5 ± 5.3 <0.001
Cardiovascular SOFA 3.32 ± 1.29 2.16 ± 1.77 <0.001
Renal SOFA 2.23 ± 1.62 1.84 ± 1.77 0.013
Hepatic SOFA 1.22 ± 1.28 1.19 ± 1.30 0.80
Respiratory SOFA 2.40 ± 1.06 1.95 ± 0.95 <0.001
Coagulation SOFA 1.33 ± 1.29 1.67 ± 1.38 0.004
Inotropic score 30 (11.9–72.5) 6.0 (0.0–22) <0.001
Lactate, mmol/L 3.4 (1.9–6.0) 1.9 (1.3–2.9) <0.001
Platelets, 103/µL 117 (56–220) 86 (40–163) <0.001
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28-day overall survival (Table 3). The variation of cardio-
vascular, respiratory and coagulation SOFA were iden-
tified as independent covariates for 28-day survival. No 
significant difference in survival was observed between 
patients receiving one or two treatments (p = 0.44).
Factors influencing the lack of cardiovascular response 
have been evaluated by a logistic regression (Table 4).
Cardiovascular and respiratory SOFA at t0 were inde-
pendent factors influencing cardiovascular response. 
Cardiovascular response was positively associated with 
the former [OR 1.51 (1.07–2.13, 95 % CI with p < 0.019)] 
and negatively with the latter [OR 0.54 (0.39–0.75, 95 % 
CI with p < 0.001)].
Cardiovascular SOFA at baseline between responders 
and non-responders (3.7 ± 0.7 vs. 3.2 ± 1.4, p ≤ 0.001) 
was significantly different. Survival rates between 
cardiovascular responders and non-responders were 
74.6 and 41.9 %, respectively (p < 0.001, Additional file 2: 
Figure S1). No significant differences in terms of age 
and SAPS II (48.6 ± 19.2 vs 51.2 ± 19.2, p = 0.32) were 
detected between the two subgroups (Additional file  1: 
Table S3).
The univariate Cox regression model identified the 
geographical origin as a factor influencing the mortality.
The characteristics of European and Asian patients are 
reported in Table 5.
Europeans were older [66 (54–74) years vs. 54 (41.3–
62), p < 0.001], their SOFA score at enrollment was lower 
(11.8 ± 3.9 vs. 15.6 ± 4.7, p < 0.001), the length of ICU 
and hospital stay was shorter [ICU LoS 11 (1–123) days 
vs. 17 (1–213), p < 0.001; hospital LoS 14.5 (2–140) days 
vs. 34 (2–407), p < 0.001], and they had a higher survival 
rate at 28-day than Asian (Additional file  3: Figure S2), 
both in the ICU (59 vs. 36.7 %, p = 0.006) and in the hos-
pital (53.2 vs. 35.0 %, p = 0.02).
The degree of cardiovascular response to PMX-HP 
treatment was similar between the two populations 
(47.4 % in European compared to 50 % in Asian patients), 
as well as the time between the diagnosis and start of the 
treatment.
Discussion
The EUPHAS 2 data collection represents the largest 
database on PMX-HP application describing its utiliza-
tion in the real clinical life. EUPHAS 2 registry was cre-
ated to describe the actual use of the PMX-HP in the 
Table 3 Cox regression on mortality stratified by age
Italics indicates significant p values
a Time between the diagnosis of severe sepsis/septic shock and PMX-HP
Univariate p Multivariate p
HR 95 % CI HR 95 % CI
Septic source
Abdominal versus respiratory 1.56 0.93–2.63 0.09 0.99 0.25–3.97 0.99
Abdominal versus urinary 0.47 0.14–1.61 0.23 0.86 0.04–16.75 0.92
Cardiovascular SOFA at t0 1.17 0.98–1.41 0.09 1.61 0.98–2.67 0.06
Coagulation SOFA at t0 1.10 0.95–1.28 0.21 0.96 0.68–1.36 0.83
Respiratory SOFA at t0 1.14 0.94–1.39 0.17 1.42 0.83–2.44 0.20
Renal SOFA at t0 0.97 0.81–1.17 0.75 0.85 0.53–1.38 0.52
Liver SOFA at t0 1.17 0.98–1.39 0.08 1.38 0.89–2.14 0.15
Δ Cardiovascular SOFA 1.39 1.20–1.62 <0.001 1.68 1.21–2.32 0.002
Δ Coagulation SOFA 1.46 1.13–1.90 0.004 1.64 1.07–2.50 0.022
Δ Respiratory SOFA 1.26 1.01–1.56 0.04 1.68 0.99–2.84 0.05
Δ Renal SOFA 1.29 0.94–1.76 0.11 0.83 0.47–1.47 0.51
Δ Liver SOFA 1.74 1.20–2.52 0.003 1.66 0.93–2.94 0.08
Timinga 0.99 0.96–1.02 0.61 0.95 0.88–1.01 0.20
European versus asiatic 0.53 0.33–0.86 0.001 2.51 0.29–22.03 0.41
Table 4 Factors influencing the lack of  cardiovascular 
response
Italics indicates significant p values
All patients Odds ratio 95 % CI p
Age 0.99 0.97–1.02 0.82
Cardiovascular SOFA at t0 1.51 1.07–2.13 <0.019
Coagulative SOFA at t0 0.96 0.75–1.24 0.78
Liver SOFA at t0 1.09 0.83–1.42 0.54
Renal SOFA at t0 1.17 0.88–1.55 0.28
Respiratory SOFA at t0 0.54 0.39–0.75 <0.001
European versus Asian 1.38 0.43–4.42 0.59
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real life collecting data from unselected populations of 
septic patiens. PMX-HP is a complementary retreatment 
applied to patients affected by severe sepsis and septic 
shock that not respond to standard care.
The registry lacked of data about fluid load adminis-
tered and hemodynamic monitor directing fluid resus-
citation. However, each center performed PMX-HP only 
after the application of international consensus recom-
mendation for sepsis, as strategy of resuscitation.
Surprisingly, in 142 patients (42  %) with clinical diag-
nosis of severe sepsis or septic shock, microbiological 
culture results were not reported that, if not performed, 
indicates a poor compliance to the bundles recommenda-
tions [20].
In 68 patients, EA was high although microbiological 
analysis did not reveal the presence of Gram negative 
germs. We can only suspect that the measured EA came 
from a Gram negative component of infection, which 
was either not revealed in microbiological tests or it was 
caused by direct translocation of endotoxin due to sepsis-
induced permeability of the gut.
PMX-HP seemed to be safe: no major adverse events 
were reported. Data analysis showed a significant platelet 
count reduction at t72 without clinical worsening of the 
Table 5 Characteristics of enrolled patients by geographical origin
Normally distributed data are expressed as mean ± SD and non-normally distributed data as median (interquartile range)
Italics indicates significant p values
Characteristics of enrolled patients by origin N = 297 N = 60 p
European Asian
Age, years 66 (54–74) 54 (41.3–62) <0.001
SOFA score at admission 10.8 ± 3.5 12.3 ± 3.4 0.16
SAPS II at admission 49.6 ± 18.0 53.8 ± 25.2 0.21
Incidence of shock N (%) 257 (86.5) 48 (80) 0.31
Septic source N (%)
 Abdominal 142 (47.8) 15 (25) 0.002
 Pulmonary 42 (14.1) 21 (35) <0.001
 Urinary 13 (4.4) 3 (5) 0.90
 Postoperative cardiac surgery 22 (7.4) 1 (1.7) 0.17
 Trauma 19 (6.4) 0 –
 Other 59 (19.9) 20 (33.3) 0.03
Days from diagnosis to enrollment N (range) 1 (0–2.0) 1.0 (0.0–1.0) 0.45
SOFA score at enrollment 11.8 ± 3.9 15.6 ± 4.7 <0.001
Cardiovascular SOFA at t0 3.4 ± 1.2 3.2 ± 1.5 0.38
Renal SOFA at t0 2.2 ± 1.6 2.6 ± 1.6 0.08
Hepatic SOFA at t0 1.1 ± 1.2 1.9 ± 1.6 <0.001
Respiratory SOFA at t0 2.3 ± 1.0 2.8 ± 1.1 0.002
Coagulation SOFA at t0 1.3 ± 1.3 1.5 ± 1.3 0.17
Inotropic score at t0 6.0 (0.0–20.3) 5.0 (0.0–49.3) 0.15
Lactate at t0, mmol/L 1.9 (1.2–2.8) 2.7 (1.5–5.2) 0.18
Platelets at t0, 10
3/µL 84 (35.3–166.8) 90 (55.0–129.0) 0.12
SOFA score at t72 10.2 ± 5.1 13.3 ± 6.4 <0.001
Cardiovascular SOFA at t72 2.2 ± 1.8 2.0 ± 1.9 0.64
Renal SOFA at t72 1.8 ± 1.8 2.2 ± 1.8 0.92
Hepatic SOFA at t72 1.1 ± 1.3 2.0 ± 1.5 0.006
Respiratory SOFA at t72 1.9 ± 0.9 2.0 ± 1.1 0.92
Coagulation SOFA at t72 1.7 ± 1.4 1.7 ± 1.2 0.72
Inotropic Score at t72 6.0 (0.0–20.3) 5.0 (0.0–49.3) 0.76
Lactates at t72, mmol/L 1.9 (1.2–2.8) 2.7 (1.5–5.2) 0.09
Platelets at t72, 10
3/µL 84 (35.3–166.8) 90 (55.0–129.0) 0.63
28-day survival, N (%) 160 (58.8) 20 (34.5) 0.003
ICU survival, N (%) 170 (59) 22 (36.7) 0.006
Hospital survival, N (%) 158 (53.2) 21 (35) 0.02
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patients. The phenomenon observed could be a manifes-
tation of the septic cascade evolution, which could alter 
platelet count and function, otherwise a complication of 
the extracorporeal technique. Data collected in the reg-
istry did not permit to establish a relationship between 
platelet decline and PMX-HP or other causes. The major-
ity of patients who experienced a severe decline in plate-
let numbers were also receiving Renal Replacement 
Therapy.
Despite the retrospective nature of EUPHAS 2 data 
collection and the lack of a control group, the relevant 
number of patients allowed a reliable statistical analysis 
of PMX-HP feasibility in a real clinical context.
Recently published epidemiologic studies reported a 
48.7  % in-hospital mortality for septic shock in France 
[26], as well as a 44 % hospital mortality for severe sepsis 
in Asian countries [27], having both the same period of 
time of EUPHAS 2. The comparison between EUPHAS 
2 and epidemiologic studies in France [26] and Asia [27] 
showed a trend to clinical improvement without signifi-
cant adverse event associated with endotoxin removal. 
Patients with abdominal infections treated within 24  h 
from the diagnosis of septic shock, had a 28-day survival 
of 64.5 %, which was comparable with 68 % observed in 
EUPHAS [15].
Recently, Zhou et al. [28] extended the analysis of effec-
tiveness to all types of extracorporeal therapies in sep-
sis RCTs and concluded that the effect on mortality was 
mainly driven by studies using PMX-HP.
Iwagami et  al. [29] published a retrospective analysis 
on 590 patients treated with PMX-HP matched through 
a propensity score to 590 patients treated with stand-
ard care who had open abdominal surgery on the day 
of admission for perforation of lower gastrointestinal 
tract, requiring the infusion of vasopressors. The authors 
showed a 28-day mortality of 17.1 % (101 of 590) in the 
PMX-HP group and 16.3  % (96 of 590) in the control 
group (p =  0.696). Data came from a nationwide inpa-
tient database in Japan, showing no benefit of PMX-HP in 
a less severe population characterized by a low mortality 
rate. However, Payen et al. in the ABDOMIX randomized 
controlled trial [16] observed an absence of benefit from 
the use of PMX membranes to treat peritonitis-induced 
septic shock after emergency surgery.
In ABDOMIX, the 28-day mortality rate was close 
to recent clinical RCTs on selected patient population 
affected by septic shock [30] unlike EUPHAS 2, which 
is a registry without specific inclusion criteria. ABDO-
MIX excluded patients affected by life-threatening 
abdominal diseases included in EUPHAS 2 as ischemia, 
obstruction, inflammatory colitis and trauma. In 
ABDOMIX, only 81 over the 119 treated patients had 
completed two sessions of PMX-HP unlike EUPHAS 
[15], in which all patients enrolled had completed the 
two PMX-HP planned with a definitely higher mortal-
ity in the control group. In ABDOMIX, the isolation of 
yeasts from peritoneum was more frequent in PMX-
treated group than in controls: this kind of disease 
represents a severe life-threatening condition not sus-
ceptible to improve by the endotoxin-adsorption blood 
purification techniques.
EUPHAS 2 confirmed that PMX-HP is often used to 
treat non-abdominal infection. The respiratory source 
was in fact the second clinical condition most fre-
quently observed in the study and in this context the 
efficacy of the PMX-HP seemed less efficient. ICU and 
hospital survival were quite similar between patients 
with abdominal and respiratory sepsis, but patients with 
respiratory infections showed a trend toward a higher 
mortality rate at 28 days (Additional file 1: Table S2).
Lower respiratory tract infections might have some dif-
ferences compared to abdominal or urinary sepsis. Pul-
monary sepsis seems to respond less to the two sessions 
of endotoxin removal because source control is substan-
tially achieved through the antibiotic action and the res-
olution needs a longer time. Differently in patients with 
intra-abdominal sepsis, the source control is obtained 
through surgery and the concomitant PMX treatment, 
achieving a more rapid resolution.
Another limitation of EUPHAS 2 is the lack of infor-
mation about patients comorbidities and early antibiotic 
therapy appropriately applied, which cannot be obtained 
from the phase 1 of the registry. The phase 2 will clarify 
the implication of these important factors related to the 
outcome.
The database included both 297 European and 60 Asian 
patients. Even if baseline characteristics of patients at 
admission were similar between the two groups except 
for the age (Asian were younger than European, respec-
tively 51.6 ± 14.7 vs 62.1 ± 14.8 years, p < 0.001), there 
was a significant difference at the enrollment to PMX-
HP in terms of SOFA score and septic source. European 
and Asiatic population were not comparable for the sep-
tic source identified: Abdominal sepsis was prevalent in 
European patients, and pulmonary sepsis was most fre-
quent in Asian patients.
Asiatic patients had a SOFA score higher than Euro-
pean patients (15.6  ±  4.7 vs 12.4  ±  4.2 respectively, 
p  <  0.001), especially for respiratory and hepatic com-
ponents. Phua et  al. [27] reported a lower compliance 
with surviving sepsis campaign bundles in Asian ICUs, 
particularly during the first 24  h. A lower adherence to 
bundles correlated with worsening clinical condition and 
higher mortality.
Both European and Asian patients showed a simi-
lar clinical effect of PMX-HP treatment on organ 
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dysfunction, that is mainly a significant reduction of 
vasopressor dependence and an improvement in gas 
exchange.
Published papers have underlined the positive effect of 
endotoxin removal by PMX-HP on cardiovascular dys-
function both increasing the arterial pressure and reduc-
ing the need of vasopressors.
In EUPHAS 2 registry, the cardiovascular component 
of SOFA represented 26.7 % of the overall score when the 
treatment was started. This means that enrolled patients 
were likely to have a high vasopressor load. Several stud-
ies showed that a higher vasopressor load is related to 
a higher risk of death in septic shock. A recent publica-
tion by Monti et al. [31] analyzed the response to PMX-
HP of patients affected by refractory septic shock. They 
concluded that an early hemodynamic improvement 
highlighted by a vasopressor load reduction, potentially 
attenuates the mortality rate. The Cox regression analy-
sis of 28-day mortality recognized the variation between 
baseline and 72  h of cardiovascular and coagulation 
components of SOFA score as independent covariates.
The similar degree of cardiovascular response to the 
PMX-HP treatment did not reflect a similar effect on 
mortality in Europe and Asia (Additional file 4: Figure 
S3, Additional file 5: Figure S4). Asian patients showed 
a lower survival rate and a higher length of stay than 
European patients, both justified by the worse organ 
dysfunction at the beginning of PMX-HP despite a car-
diovascular response similar to European patients. The 
worse outcome of Asian patients could be related to the 
lower adherence to sepsis guideline and the higher inci-
dence of respiratory infection than European patients.
In conclusion, notwithstanding the retrospective 
nature of the present data collection and the lack of a 
control group, these data confirmed the feasibility of the 
PMX-HP application in the usual clinical context without 
life-threatening adverse events related to its application, 
as already described in previous RCTs and observational 
studies. The ongoing EUPHRATES RCT [32] will clarify 
the effective clinical collocation of PMX-HP in patients 
suffering from endotoxin-mediated septic shock.
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